JBIO

Jade Biosciences, Inc. NASDAQ Listed Apr 29, 2025

Healthcare ·Biotechnology ·US · jadebiosciences.com

$24.25

Mkt Cap $791.2M

52w Low $6.57 82.5% of range 52w High $28.00

50d MA $17.81 200d MA $12.79

P/E (TTM) -6.0x

EV/EBITDA -3.5x

P/B 2.3x

Debt/Equity 0.0x

ROE -38.3%

P/FCF -5.1x

RSI (14) —

ATR (14) —

Beta 1.03

50d MA $17.81

200d MA $12.79

Avg Volume 477.6K

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

SIC Code

2834

CIK (SEC)

1798749

Phone

1 916-322-1700

221 Crescent Street Building 23 · Waltham, MA 02453 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 6, 2026	AMC	-0.45	-0.11	+75.6%	14.05	+2.8%	+2.7%	+3.1%	-0.2%	-1.4%	-0.9%	—
Nov 13, 2025	AMC	-0.57	-0.48	+15.8%	9.68	-0.8%	+10.5%	+30.1%	+30.7%	+28.7%	+18.6%	—
Aug 13, 2025	AMC	-0.43	-0.86	-100.0%	7.33	+5.9%	-7.6%	+0.4%	+2.3%	+0.4%	-6.5%	—
Apr 25, 2025	AMC	-8.40	-0.09	+98.9%	93.80	-0.7%	+0.0%	-89.2%	-89.9%	-89.3%	-86.7%	—
Mar 27, 2025	AMC	-0.19	-0.19	+0.0%	88.55	+0.8%	+0.0%	-0.8%	-0.8%	-0.4%	-0.8%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.98	$25.78	+3.2%	+7.5%	+5.9%	-10.6%	-2.3%	-3.0%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.26	$13.58	+2.4%	+5.2%	+5.2%	+1.0%	+0.0%	+6.0%
Mar 16	BTIG	Maintains	Buy → Buy	—	$13.92	$14.79	+6.2%	+2.4%	+0.4%	-1.0%	+1.1%	+0.6%
Mar 11	Guggenheim	Maintains	Buy → Buy	—	$14.48	$14.90	+2.9%	-3.2%	-4.3%	-3.9%	-1.6%	-3.5%
Mar 9	Wedbush	Maintains	Outperform → Outperform	—	$14.05	$14.44	+2.8%	+2.7%	+3.1%	-0.2%	-1.4%	-0.9%
Nov 18	Guggenheim	Maintains	Buy → Buy	—	$12.59	$12.84	+2.0%	+0.5%	-1.0%	-8.8%	-4.7%	-3.5%
Aug 14	Wedbush	Maintains	Outperform → Outperform	—	$7.33	$7.76	+5.9%	-7.6%	+0.4%	+2.3%	+0.4%	-6.5%
Jun 16	Guggenheim	Upgrade	Neutral → Buy	—	$6.76	$7.25	+7.2%	+3.4%	+22.6%	+39.2%	+46.3%	+46.0%
May 15	Wedbush	Maintains	Outperform → Outperform	—	$7.55	$7.50	-0.7%	-2.0%	-2.8%	-1.7%	+2.3%	-0.8%

Data updated apr 25, 2026 4:43pm · Source: massive.com